Inhalation Home

The only technical publication devoted exclusively to readers involved in development
and production of pulmonary or nasal delivered pharmaceuticals.

Article Archive

Browse by Subject Browse by Organization Browse by Author

Cross Industry Organizations
Tablets & Capsules
INH Magazine

Cover Photo Courtesy of
Gateway Analytical

Download Table of Contents

This Month’s Focus: Devices

Connected inhalers: Stakeholders’ potential benefits and possible concerns

There are compelling situations that argue for the benefits that connected inhalers may provide patients, the primary benefit being better patient outcomes. Potential benefits for and possible concerns of healthcare providers, pharmacies, pharmaceutical manufacturers and payers are discussed.

Spray-granulated mannitol as a viable alternative to lactose in DPI formulations: Preparation of ordered mixtures and storage stability

A study of the influence of blend preparation and storage stability of a mannitol carrier material in DPI formulations

General Features

Back Page: The Teal Pumpkin Project helps children with food allergies celebrate Halloween safely

The project encourages people to offer non-food treats as an alternative to candy to make the holiday more inclusive and help ensure children with food allergies enjoy a safer, happier holiday.

Cross-Industry Organizations: The Respiratory Drug Delivery Conferences: Cascade impaction is not just for aerosols anymore

“Cascade impaction” can describe the networking environment at the RDD conferences. It is one of the reasons delegates attend RDD (in the US), RDD Europe and RDD Asia.

Previewing PharmSci360 2018

The 2018 AAPS annual meeting, now named PharmSci360, will be held November 4-7, 2018 in Washington, DC, US.

A preview of DDL2018 and the IPAC-RS workshop

Drug Delivery to the Lungs (DDL) 2018 will take place Decem¬ber 12-14, 2018 at the Edinburgh International Conference Centre in Edinburgh, UK.

December Content

General chapter development for OINDPs at the USP: Part 2—Informative chapters <1601>, <1602>, <1603> and <1604>

Respirable engineered spray-dried dry powders for 505(b)(2) drug product development

Back Page: The pediatric asthma yardstick

Cross-industry organizations: ISAM

Drug Delivery Partnerships 2019

Issue focus: Quality/Compliance

Special section: Capsules/Blisters

Issue Focuses

January: Reference and Buyer’s Resource

February: Product Development/ Contract Testing

April: Instruments

June: Nasal Delivery/Nebulizers

August: Particle Characterization

October: Devices

December: Quality/Compliance

Contact the editor:
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
Fax 651-287-5650

Inhalation Article Guidelines

Technical article requirements

The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.

All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner.

The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.

We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.

Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.

Editorial board review and production

All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.

Special Sections
Reference & Buyer’s Resource
Product Development/
Contract Testing
Formulation Development/
Nasal Delivery/Nebulizers
Particle Characterization
Particle Manufacturing
Outsourcing Services
Buyers Guide
Inhalation 1-2-3